Insmed IncINSM
ASignal's systematic analysis rates INSM as Neutral.
Reflects the latest available analysis · analyzed Aug 23, 2026
The case on INSM
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (296.1% YoY)
- High gross margin (83.45%) indicating pricing power
- Positive cash position with $1.16B cash vs $739.72M debt
- Current ratio of 3.72x suggests strong liquidity
- Analyst coverage from reputable sources including SeekingAlpha and Zacks
- RSI at 71.55 indicating overbought conditions
- Negative operating cash flow (-$778.92M)
- Negative free cash flow (-$571.82M)
- Negative profit and operating margins
- High forward P/E of 174.71x and negative EV/EBITDA suggest elevated valuation risks
- No Reddit mentions, indicating low retail investor interest
See the full verdict on INSM
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes INSM
Most investors never get a second opinion, let alone several. ASignal runs INSM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.